Evidence map›Paper›PMID 41760327›Full record

ArticleIn vivo (Athens, Greece)

Ultra-low Concentrations of Cisplatinum Down to the IC

Yohei Asano, Qinghong Han, Shukuan Li, Byung Mo Kang, Jin Soo Kim, Yuta Miyashi, Michael Bouvet, Norio Yamamoto, Katsuhiro Hayashi, Hiroaki Kimura and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yohei AsanoAntiCancer Inc., San Diego, CA, U.S.A.
Qinghong HanAntiCancer Inc., San Diego, CA, U.S.A.
Shukuan LiAntiCancer Inc., San Diego, CA, U.S.A.
Byung Mo KangAntiCancer Inc., San Diego, CA, U.S.A.
Jin Soo KimAntiCancer Inc., San Diego, CA, U.S.A.
Yuta MiyashiAntiCancer Inc., San Diego, CA, U.S.A.
Michael BouvetDepartment of Surgery, University of California, San Diego, CA, U.S.A.
Norio YamamotoDepartment of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
Katsuhiro HayashiDepartment of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
Hiroaki KimuraDepartment of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
Shinji MiwaDepartment of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
Kentaro IgarashiDepartment of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
Takashi HiguchiDepartment of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
Sei MorinagaDepartment of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
Hiroyuki TsuchiyaDepartment of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
Satoru DemuraDepartment of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
Robert M HoffmanAntiCancer Inc., San Diego, CA, U.S.A.; all@anticancer.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimTo determine whether methionine restriction using recombinant methioninase (rMETase) enhances the efficacy of ultra-low-dose cisplatinum against lung cancer cells MATERIALS AND

methodsHuman A549 lung adenocarcinoma cells were treated with rMETase and cisplatinum

resultsFor A549 lung-cancer cells the IC

conclusionMethionine restriction enhances the efficacy of ultra-low-dose cisplatinum on lung cancer cells

Indexed as

Antineoplastic AgentsCarbon-Sulfur LyasesCisplatinLung NeoplasmsRecombinant ProteinsA549 CellsAnimalsCell Line, TumorCell ProliferationCell SurvivalDisease Models, AnimalDrug SynergismHumansMethionineMiceMice, NudeAntineoplastic AgentsCarbon-Sulfur LyasesCisplatinL-methionine gamma-lyaseMethionineRecombinant ProteinscisplatinumcombinationHoffman effectin vitrolung cancerMethionine addictionmethionine restrictionmicrodosenude micerecombinant methioninase (rMETase)synergy

Identifiers

PMID41760327
PMCPMC12949898

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.